Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2002

View Archived Issues

Novel anticholinergics and their use in asthma, COPD, etc.

Boehringer Ingelheim claims new agents for urinary incontinence

DPP-IV inhibitors and their use in diabetes and related disorders reported by Tanabe

Shionogi develops novel MMP inhibitors

Yamanouchi presents mGluR1 modulators useful in stroke

cGMP-selective PDE inhibitors in early development at Nippon Soda

Preclinical profile of AZD-3582 highlighted at EULAR 2002

Japanese approval obtained for Elaspol

Virucidal activity of liposomal povidone-iodine

Antioxidant and cardioprotective effects of resveratrol and astringinin

MEDICA 16 inhibits hepatic acetyl-CoA carboxylase in insulin-resistant rats

Significant beneficial effects on health-related QOL seen in RA patients treated with CDP-870

Pegylated Axokine enters phase I for treatment of obesity

Patent coverage obtained for Mindset's lead AD therapeutic candidate

Improvement in glucose tolerance in ZDF rats treated with NVP-DPP-728

FDA approves Celebrex labeling changes

Pfizer to return rights to UK-279276 to Corvas

Miltefosine designated an orphan drug for black fever

Essential Therapeutics updates development program objectives

Antidiabetic activity of PPARgamma ligand related to effects on DPP-IV

Chromium supplementation lowers blood glucose, insulin requirements in type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...